| Entry |
|
|---|
| Name |
Candesartan (USAN/INN) |
|---|
| Formula |
C24H20N6O3
|
|---|
| Exact mass |
440.1597
|
|---|
| Mol weight |
440.454
|
|---|
| Structure |
|
|---|
| Simcomp |
|
|---|
| Class |
Cardiovascular agent
DG01925 Renin-angiotensin system inhibitor
DG01495 Angiotensin II receptor antagonist
DG03231 Antihypertensive
DG01495 Angiotensin II receptor antagonist
Metabolizing enzyme substrate
DG01642 CYP2C9 substrate
|
|---|
| Remark |
| Product (DG00350): | D00626<JP/US> |
|
|---|
| Efficacy |
Antihypertensive, Angiotensin II receptor antagonist |
|---|
| Target |
|
|---|
| Pathway |
| hsa04080 | Neuroactive ligand-receptor interaction |
| hsa04261 | Adrenergic signaling in cardiomyocytes |
| hsa04270 | Vascular smooth muscle contraction |
|
|---|
| Metabolism |
Enzyme: CYP2C9 [HSA: 1559]
|
|---|
| Interaction |
|
|---|
| Structure map |
| map07229 | Angiotensin receptor and endothelin receptor antagonists |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
C CARDIOVASCULAR SYSTEM
C09 AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
C09C ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN
C09CA Angiotensin II receptor blockers (ARBs), plain
C09CA06 Candesartan
D00522 Candesartan (USAN/INN)
Drug groups [BR:br08330]
Cardiovascular agent
DG01925 Renin-angiotensin system inhibitor
DG01495 Angiotensin II receptor antagonist
DG00350 Candesartan
D00522 Candesartan
DG03231 Antihypertensive
DG01495 Angiotensin II receptor antagonist
DG00350 Candesartan
D00522 Candesartan
Metabolizing enzyme substrate
DG01642 CYP2C9 substrate
DG00350 Candesartan
D00522 Candesartan
Target-based classification of drugs [BR:br08310]
G Protein-coupled receptors
Rhodopsin family
Angiotensin
AGTR1
D00522 Candesartan (USAN/INN)
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D00522
Prodrugs [br08324.html]
D00522
Drug groups [BR:br08330]
Cardiovascular agent
DG01925 Renin-angiotensin system inhibitor
DG01495 Angiotensin II receptor antagonist
DG00350 Candesartan
DG03231 Antihypertensive
DG01495 Angiotensin II receptor antagonist
DG00350 Candesartan
Metabolizing enzyme substrate
DG01642 CYP2C9 substrate
DG00350 Candesartan
|
|---|
| Other DBs |
|
|---|
| KCF data |
ATOM 33
1 C8y C 22.0850 -15.5109
2 N4y N 21.6416 -14.1867
3 C8y C 23.4790 -15.5166
4 C8y C 21.3850 -16.7182
5 C8y C 22.7790 -13.3526
6 C1b C 20.4167 -13.4984
7 N5x N 23.9165 -14.1867
8 C8x C 24.1731 -16.7241
9 C8x C 22.0790 -17.9257
10 C6a C 20.6733 -17.9199
11 O2a O 22.7790 -11.9526
12 C8y C 19.2150 -14.2217
13 C8x C 23.4731 -17.9316
14 O6a O 19.2733 -17.9082
15 O6a O 21.3557 -19.1331
16 C1b C 23.9922 -11.2526
17 C8x C 17.9842 -13.5392
18 C8x C 19.2441 -15.5984
19 C1a C 23.9922 -9.8526
20 C8x C 16.7826 -14.2625
21 C8x C 18.0309 -16.3450
22 C8y C 16.8176 -15.6625
23 C8y C 15.6102 -16.3799
24 C8y C 14.3794 -15.7032
25 C8x C 15.6335 -17.7798
26 C8y C 14.3560 -14.2975
27 C8x C 13.1836 -16.4208
28 C8x C 14.4318 -18.5032
29 N4x N 13.2243 -13.4925
30 N5x N 15.4877 -13.4517
31 C8x C 13.2127 -17.8265
32 N5x N 13.6327 -12.1509
33 N5x N 15.0326 -12.1277
BOND 37
1 1 2 1
2 1 3 2
3 1 4 1
4 2 5 1
5 2 6 1
6 3 7 1
7 3 8 1
8 4 9 2
9 4 10 1
10 5 11 1
11 6 12 1
12 8 13 2
13 10 14 1
14 10 15 2
15 11 16 1
16 12 17 1
17 12 18 2
18 16 19 1
19 17 20 2
20 18 21 1
21 20 22 1
22 22 23 1
23 23 24 1
24 23 25 2
25 24 26 1
26 24 27 2
27 25 28 1
28 26 29 1
29 26 30 2
30 27 31 1
31 29 32 1
32 30 33 1
33 5 7 2
34 9 13 1
35 21 22 2
36 28 31 2
37 32 33 2
|
|---|
